Canada - English - Health Canada

aa pharma inc - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents

Canada - English - Health Canada

ratiopharm inc division of teva canada limited - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents

Canada - English - Health Canada

nu-pharm inc - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - pentoxifylline - oral solution - 40mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - pentoxifylline - oral solution - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - pentoxifylline - oral suspension - 20mg/1ml

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablet should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets, usp are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.